
==== Front
Schizophrenia (Heidelb)
Schizophrenia (Heidelb)
Schizophrenia
2754-6993
Nature Publishing Group UK London

39223235
497
10.1038/s41537-024-00497-7
Article
Gut microbiome and schizophrenia: insights from two-sample Mendelian randomization
Zhou Keer 1
Baranova Ancha 23
Cao Hongbao 2
Sun Jing jingsun2007@163.com

1
http://orcid.org/0000-0003-3204-8191
Zhang Fuquan zfqeee@126.com

14
1 grid.89957.3a 0000 0000 9255 8984 Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China
2 https://ror.org/02jqj7156 grid.22448.38 0000 0004 1936 8032 School of Systems Biology, George Mason University, Manassas, VA USA
3 https://ror.org/03dhz7247 grid.415876.9 Research Centre for Medical Genetics, Moscow, Russia
4 grid.89957.3a 0000 0000 9255 8984 Institute of Neuropsychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, China
2 9 2024
2 9 2024
2024
10 1 7522 4 2024
14 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Growing evidence suggests a potential link between the gut microbiome and schizophrenia. However, it is unclear whether the gut microbiome is causally associated with schizophrenia. We performed two-sample bidirectional Mendelian randomization to detect bidirectional causal relationships between gut microbiome and schizophrenia. Summary genome-wide association study (GWAS) datasets of the gut microbiome from the MiBioGen consortium (n = 18,340) and schizophrenia (n = 130,644) were utilized in our study. Then a cohort of sensitive analyses was followed to validate the robustness of MR results. We identified nine taxa that exerted positive causal effects on schizophrenia (OR: 1.08–1.16) and six taxa that conferred negative causal effects on schizophrenia (OR: 0.88–0.94). On the other hand, the reverse MR analysis showed that schizophrenia may increase the abundance of nine taxa (OR: 1.03–1.08) and reduce the abundance of two taxa (OR: 0.94). Our study unveiled mutual causal relationships between gut microbiome and schizophrenia. The findings may provide evidence for the treatment potential of gut microbiomes in schizophrenia.

Subject terms

Schizophrenia
Microbiology
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Schizophrenia is a psychiatric disorder characterized by psychotic symptoms, negative symptoms, and cognitive dysfunction1. A systematic analysis (2019) reported that schizophrenia had the highest disability weight for acute psychotic compared to other mental disorders2. It is generally accepted that antipsychotic drugs are effective in relieving psychotic symptoms by increasing dopamine activity. However, antipsychotic drug efficacy in schizophrenia seems to decline, especially in negative symptoms and depression3. Therefore, it is urgent to investigate the potential mechanism of schizophrenia and to aid an efficient treatment plan.

The gut microbial composition differs in persons with schizophrenia and controls4. Besides often discussed drug-induced microbiome changes, several studies have shown that abundances of gut microbiota species differ between untreated patients with schizophrenia and age-matched healthy volunteers5–7. This is probably because the function of the gut-brain axis can be regulated by the gut microbiome. The gut microbiota and brain influence each other mutually through multiple pathways, such as the immune system, tryptophan metabolism, the vagus nerve and the enteric nervous system, and microbial metabolites including short-chain fatty acids, branched-chain amino acids, and peptidoglycans8. Targeting the axis, several attempts have been made to interrupt the progression of schizophrenia, including fecal microbiota transplantation, probiotic supplements, prebiotic treatment, and antibiotics9. Furthermore, the opportunities for the microbiome to become a diagnostic tool were discussed in some diseases9,10. Nevertheless, articles have emerged that offer diverse findings recently. Zhu et al. mentioned that Streptococcus vestibularis was enriched in individuals with schizophrenia and, when transplanted to recipient mice, was found to lead to deterioration in social behaviors5. According to Nguyen et al., phylum Proteobacteria, genus Haemophilus, Sutterella, and Clostridium were found to be relatively decreased in schizophrenia subjects while the genus Anaerococcus was increased11. Unlike Nguyen, in Błażej et al.’s case-control study, generally increased Lactobacillales (order level), Bacilli (class level), and Actinobacteriota (phylum level) were found in schizophrenia patients12. Furthermore, the biological mechanisms related to gut microbiota may play a crucial role in other mental diseases, such as mild cognitive impairment, depression, and Alzheimer’s disease13–17. Thus, whether the causal associations between gut microbiome and schizophrenia exist remains unclear.

Mendelian randomization (MR) has an edge over other conventional observational studies aimed at assessing causal associations. MR constructs instrumental variables of exposure by harnessing genetic variants18. During gamete formation and conception, parents pass on genes to offspring randomly. Therefore, MR can investigate the relationships between exposure and outcome without disturbance of reverse causation or confounding variables19. This approach is increasingly used to infer causality for mental disorders20–22.

In this study, we conducted a two-sample MR analysis to identify the associations between gut microbiome and schizophrenia using statistics derived from a genome-wide association study (GWAS) from the MiBioGen and the Psychiatric Genomics Consortium (PGC).

Methods

Data sources

Summary statistics of gut microbiome were obtained from a large-scale, multi-ancestry, genome-wide meta-analysis, also known as the MiBioGen research. Including 18,340 participants from 24 cohorts over 11 countries (16 cohorts from European ancestry, n = 13,266), the study characterized microbial composition from three distinct variable regions of the 16S rRNA gene: V4, V3–V4, and V1–V2. After rarefied every sample to 10,000 reads, they took advantage of direct taxonomic binning to perform taxonomic classification. Microbiome trait Loci (mbTL) were mapped to identify microbiome quantitative trait loci (mbQTL) or microbiome binary trait loci (mbBLT)23. GWAS summary statistics of schizophrenia, obtained from PGC, included 77,285 individuals with schizophrenia and 53,386 control individuals, with most subjects being of European ancestry, containing common variant associations at 287 distinct genomic loci. It is the largest schizophrenia GWAS statistic and has an enlarged number of associated loci24.

Instrumental variable (IV)

We chose candidate instrumental variables at the genome-wide significance threshold p < 1.0 × 10−5. Independent SNPs were selected by clumping in a 10,000 Kb window and setting a linkage disequilibrium threshold of r2 < 0.001. Linkage disequilibrium was estimated by 1000 Genomes phase 3 European samples25.

Statistics analysis

The package “TwoSampleMR” was utilized for all the MR analyses. Three methods including inverse variance weighted (IVW), MR-Egger, and weighted median were applied to calculate the causal effect of gut microbiota on schizophrenia. Cochrane’s Q test in the IVW test and I2 statistics (p < 0.05 and I2 > 0.25) were carried out, aiming at assessing whether there exists potential heterogeneity. Under the premise that the association of each genetic variant with the exposure is independent of its pleiotropy, the MR-Egger provides an efficient test for meta-analysis to detect study bias from horizontal pleiotropy. The true causal effect can be estimated from the slope coefficient of Egger regression26. Then we performed MR-PRESSO analyses to detect the potential horizontal pleiotropy by removing significant outliers27. We calculated the F-statistic to assess the strength of instrumental variables. If the F-statistic of the instrumental variable was less than 10, then this instrument was considered as weak and was excluded from the MR analysis28. The weighted median can be considered a sensitivity analysis for Mendelian randomization investigations and supplementary to MR-Egger29. We prefer to use the inverse variance weighted method as a major method in the analysis because consistent and robust estimates were given under the circumstance that all of the genetic variants are valid instrumental variables.

We performed a reverse Mendelian Randomization analysis in our study to detect the potential causal effects of schizophrenia on the gut microbiome. The same methods and procedures were adopted when we conducted the reverse MR analysis.

Results

In the MR analysis of summary association statistics of gut microbiome and schizophrenia, the numbers of the instrumental variables vary from 5 to 22. The MR-PRESSO analysis identified a total of 6 SNPs as significant outliers for two of the taxa studied (class Betaproteobacteria: rs11128180, rs2321387, rs2613606; genus Eubacterium fissicatena group: rs10147907, rs151257695, rs2733072), suggesting the horizontal pleiotropy may exist in the effect of the two taxa on schizophrenia (Supplementary 1). According to the MR-PRESSO global test, no horizontal pleiotropy was found in any other MR result. After removing these outliers, the leftover SNPs were selected as instrumental variables for subsequent re-run of MR analysis.

The result of IVW suggests that nine taxa were positively correlated with schizophrenia risk, including phylum Firmicutes, class Betaproteobacteria, class Clostridia, order Clostridiales, family Prevotellaceae, genus Alloprevotella, genus FamilyXIIIUCG001, genus Hungatella, and genus Subdoligranulum (OR: 1.08–1.16, p ≤ 0.044). On the other hand, six taxa served as protective factors for schizophrenia, including family Rhodospirillaceae, family Defluviitaleaceae, family Veillonellaceae, genus Coprobacter, genus Gordonibacter, and genus Desulfovibrio (OR: 0.88–0.94, p ≤ 0.049) (Table 1 and Figs. 1A and 2A). The causal effect of class Clostridia, family Rhodospirillaceae, and genus Desulfovibrio on schizophrenia was also supported by the weighted median method. Additionally, the effect direction of the weighted median is consistent with the IVW estimate. However, none of the associations were significant after correction for FDR (p < 0.05). There is no horizontal pleiotropy since the p values of the MR-Egger regression test are all greater than 0.05. The result of Cochran’s IVW Q test revealed significant heterogeneity in the instrumental variables of class Betaproteobacteria (p = 0.010, I2 = 55.3%).Table 1 MR results of the causal effects of the gut microbiome on schizophrenia.

Exposure	Outcome	OR [95% CI]	p	
Class Betaproteobacteria	Schizophrenia	1.13 [1.01–1.27]	0.027	
Class Clostridia	Schizophrenia	1.16 [1.05–1.28]	4.22E−03	
Family Defluviitaleaceae	Schizophrenia	0.92 [0.85–1.00]	0.041	
Family Prevotellaceae	Schizophrenia	1.11 [1.03–1.20]	1.36E−03	
Family Rhodospirillaceae	Schizophrenia	0.93 [0.87–1.00]	0.049	
Family Veillonellaceae	Schizophrenia	0.93 [0.87–0.99]	0.033	
Genus Alloprevotella	Schizophrenia	1.09 [1.02–1.16]	7.88E−03	
Genus Coprobacter	Schizophrenia	0.92 [0.86–0.98]	7.29E−03	
Genus Desulfovibrio	Schizophrenia	0.88 [0.82–0.96]	1.89E−03	
Genus FamilyXIIIUCG001	Schizophrenia	1.14 [1.00–1.29]	0.044	
Genus Gordonibacter	Schizophrenia	0.94 [0.89–0.99]	0.012	
Genus Hungatella	Schizophrenia	1.08 [1.00–1.17]	0.043	
Genus Subdoligranulum	Schizophrenia	1.14 [1.03–1.27]	0.015	
Order Clostridiales	Schizophrenia	1.12 [1.01–1.24]	0.027	
Phylum Firmicutes	Schizophrenia	1.11 [1.02–1.21]	0.015	
CI confidence interval, OR odds ratio, p p value.

Fig. 1 Causal effects between the gut microbiome and schizophrenia (forest plot).

A Causal effects of the gut microbiome on schizophrenia. B Causal effects of schizophrenia on the gut microbiome. CI confidence interval, OR odds ratio, P p value.

Fig. 2 Causal effects between the gut microbiome and schizophrenia (scatter plot).

A Causal effects of the gut microbiome on schizophrenia. B Causal effects of schizophrenia on the gut microbiome. b MR estimate, P p value.

In the reverse MR analysis between schizophrenia and gut microbiome, we found that schizophrenia may increase the abundance of nine taxa, including class Verrucomicrobiae, family Bacteroidaceae, family Verrucomicrobiaceae, genus Akkermansia, genus Bacteroides, genus Candidatus Soleaferrea, genus Lachnospira, genus Ruminiclostridium5, and order Verrucomicrobiales (OR: 1.03–1.08, p ≤ 0.04); while schizophrenia may reduce the abundance of family Defluviitaleaceae and genus DefluviitaleaceaeUCG011 (OR: 0.94, p ≤ 7.12 × 10−3) (Table 2 and Figs. 1B and 2B). No evidence of pleiotropy and heterogeneity was found according to the MR-Egger regression intercept analysis, MR-PRESSO analysis, and Q test in IVW.Table 2 MR results of the causal effects of schizophrenia on the gut microbiome.

Exposure	Outcome	OR [95% CI]	p	
Schizophrenia	Class Verrucomicrobiae	1.04 [1.00–1.09]	0.039	
Schizophrenia	Family Bacteroidaceae	1.03 [1.00–1.07]	0.039	
Schizophrenia	Family Defluviitaleaceae	0.94 [0.90–0.98]	7.12E−03	
Schizophrenia	Family Verrucomicrobiaceae	1.04 [1.00–1.09]	0.039	
Schizophrenia	Genus Akkermansia	1.04 [1.00–1.09]	0.040	
Schizophrenia	Genus Bacteroides	1.03 [1.00–1.07]	0.039	
Schizophrenia	Genus Candidatus Soleaferrea	1.08 [1.02–1.14]	5.19E−03	
Schizophrenia	Genus DefluviitaleaceaeUCG011	0.94 [0.90–0.98]	7.06E−03	
Schizophrenia	Genus Lachnospira	1.04 [1.00–1.07]	0.036	
Schizophrenia	Genus Ruminiclostridium5	1.05 [1.02–1.08]	3.03E−03	
Schizophrenia	Order Verrucomicrobiales	1.04 [1.00–1.09]	0.039	
CI confidence interval, OR odds ratio, p p value.

Discussion

Our study revealed causal associations between gut microbiome and schizophrenia. We identified nine bacterial features positively and six bacterial features negatively correlated with schizophrenia. In addition, there exist reverse effects from schizophrenia to 11 identified bacterial features.

We reported that the genus Desulfovibrio appeared to be associated with schizophrenia, supported by both the IVW test and the weighted median method. Previous studies highlighted the significance of the genus Desulfovibrio and its metabolism in the pathophysiology of schizophrenia30. A pilot study reported that for patients with exacerbated symptoms of schizophrenia, taking the treatment of schizophrenia with amisulpride cannot change the elevated level of Desulfovibrio in gut microbial composition31. Antipsychotic agents might result in constipation by affecting gastrointestinal motility, and the relative abundance of Desulfovibrio was higher in psychopaths with constipation32.

Our result unveiled that phylum Firmicutes was positively correlated with schizophrenia. A study utilizing the polyriboinosinic-polyribocytidylic (Poly I:C) mouse model reported that the increased level of phylum Firmicutes which activate the immune system might account for neuroplasticity reduction in cortical areas in patients with schizophrenia33. However, recent studies yielded conflicting results. Numerous studies have compared the composition of the intestinal microflora in schizophrenia patients and healthy volunteers, showing that schizophrenia patients have a lower relative abundance of Firmicutes at the phylum level34,35. Xiang et al. observed an increased abundance of Firmicutes in the fecal microbiota of patients with schizophrenia after 14–19 days of antipsychotic treatment36.

As shown in MR results, class Betaproteobacteria is also a risk factor for schizophrenia. In a case-control study, the cognitive function was positively correlated with class Betaproteobacteria in patients with schizophrenia, suggesting that the alternations of the gut microbiome may partly account for the cognitive impairment in schizophrenia6.

We also demonstrated that the class Clostridia and order Clostridiales were causally associated with a higher risk of schizophrenia, which was in line with previous studies37,38, He et al. carried out a series of experiments and observed that the abundance of the order Clostridiales was elevated in subjects at ultra-high risk for psychosis, which produced more Short Chain Fatty Acids (SCFAs). These SCFAs contribute to the activation of microglial cells and the membrane dysfunction confirmed by an increase in choline levels39. Conversely, Li et al. pointed out that the depletion of Clostridiales might mediate schizophrenia through an imbalance in amino acid metabolism and carbohydrate metabolism40. In social isolation rats (an animal model for schizophrenia), decreases in the class Clostridia are probably associated with the increase in several indices of “anxiety-like” behavior and the dysfunction in learning and memory41.

Along with previous studies, the family Prevotellaceae was found to be positively correlated with the risk of schizophrenia in our study37,42. A recent comparative study by Chen et al. involved the gut microbiota structure in schizophrenia patients with violence and without violence. They found more enriched Family Prevotellaceae in schizophrenia patients with violence than in those without violence, which would probably be instrumental to a deeper understanding of the etiology of violence43. Lee et al.’s research reported a differential abundance of Prevotella and Prevotellaceae NK3B31 group in patients with the deficit subtype of schizophrenia compared with those with non-deficit schizophrenia and healthy controls. Correlations between these alternations of gut microbiome and cognitive performance were found in patients who participated in the study44.

Family Veillonellaceae was reported to exert protective effects in schizophrenia in our findings. Schizophrenia patients with violence had impoverished Veillonellaceae compared to those without violence, implying its involvement in violent behaviors43. By contrast, another study observed that the family Veillonellaceae was increased in patients with schizophrenia. In addition, lower glutamate and higher glutamine and GABA in the hippocampus were observed in the mice receiving schizophrenia microbiome fecal transplants, which indicates that the pathology of schizophrenia may be relevant to the alternation of neurochemistry caused by the change of intestinal microbiome42.

In our MR analysis, we identified the genus Family XIII UCG00 and the genus Hungatella that were positively associated with schizophrenia, while the genus Coprobacter was negatively associated with schizophrenia. A broadly similar result of a recent comparative study showed that higher abundances of the Family XIII AD3011 group, Hungatella, and Coprobacillus were found in patients with schizophrenia. The interactions between inflammatory cytokines, gut permeability, lipid metabolism, impaired glucose homeostasis, and gut microbiota alterations probably mediate cognitive impairment, severe psychotic symptoms, and worse social functioning. For example, the level of zonulin appeared to regulate the performance of attention45. Borkent et al. also argued that gastrointestinal barrier dysfunction which increases intestinal permeability serves as a potential cause for schizophrenia46. Several attempts have been made to improve the efficacy of treatments in schizophrenia, such as fecal microbiota transplantation47, probiotic supplement48, and prebiotic treatment49, further supporting the role of the gut microbiome and gut-brain axis in schizophrenia. Zheng et al. reported that antipsychotic medication like amisulpride may exert its therapeutic action by influencing the gut microbiome31. Similarly, it was hypothesized that both probiotics and repetitive transcranial magnetic stimulation (rTMS) alleviate schizophrenia symptoms by influencing the gut microbiome50–52. These previous studies show us a promising avenue for the therapy of psychiatric conditions by manipulating the gut-brain axis.

Notably, Mendelian Randomization uses inherited genetic variation underlining each trait as an instrumental variable to detect the association between gut microbiome and schizophrenia. These genetic variants are inherited from parents and will not change after birth, which makes confounding factors less likely to affect these variables16,17.

Nevertheless, the study comes with several limitations. First, the majority of participants in the GWAS data had European ancestry, thus our study may not be suitable for the non-European population. Second, none of our MR results remained significant after the multiple correction. Third, in our study, we did not take some vital environmental factors into consideration, including the effects of diet and medication on the disease progression.

Conclusion

In summary, we comprehensively unveiled the bidirectional causal relationship between gut microbiome and schizophrenia. Our findings probably provide novel insights into the pathology and treatment of schizophrenia.

Supplementary information

Supplementary Information

Supplementary information

The online version contains supplementary material available at 10.1038/s41537-024-00497-7.

Acknowledgements

We thank members of all consortia, who generously shared the GWAS data. We have no funding or support.

Author contributions

All authors contributed to the revision of the manuscript. All authors approved the final version.

Data availability

All de-identified data are publicly available.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Marder SR Cannon TD Schizophrenia N. Engl. J. Med. 2019 381 1753 1761 10.1056/NEJMra1808803 31665579
Marder, S. R. & Cannon, T. D. Schizophrenia. N. Engl. J. Med. 381, 1753–1761 (2019).31665579 10.1056/NEJMra1808803
2. GBD 2019 Mental Disorders Collaborators. Global, regional and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry 9, 137–150 (2022).
3. Leucht S Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors Am. J. Psychiatry 2017 174 927 942 10.1176/appi.ajp.2017.16121358 28541090
Leucht, S. et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, Bayesian meta-analysis, and meta-regression of efficacy predictors. Am. J. Psychiatry 174, 927–942 (2017).28541090 10.1176/appi.ajp.2017.16121358
4. Murray N Compositional and functional alterations in intestinal microbiota in patients with psychosis or schizophrenia: a systematic review and meta-analysis Schizophr. Bull. 2023 49 1239 1255 10.1093/schbul/sbad049 37210594
Murray, N. et al. Compositional and functional alterations in intestinal microbiota in patients with psychosis or schizophrenia: a systematic review and meta-analysis. Schizophr. Bull. 49, 1239–1255 (2023).37210594 10.1093/schbul/sbad049
5. Zhu F Metagenome-wide association of gut microbiome features for schizophrenia Nat. Commun. 2020 11 1612 10.1038/s41467-020-15457-9 32235826
Zhu, F. et al. Metagenome-wide association of gut microbiome features for schizophrenia. Nat. Commun. 11, 1612 (2020).32235826 10.1038/s41467-020-15457-9
6. Ma J Song XQ Correlation between cognitive impairment and metabolic imbalance of gut microbiota in patients with schizophrenia World J. Psychiatry 2023 13 724 731 10.5498/wjp.v13.i10.724 38058688
Ma, J. & Song, X. Q. Correlation between cognitive impairment and metabolic imbalance of gut microbiota in patients with schizophrenia. World J. Psychiatry 13, 724–731 (2023).38058688 10.5498/wjp.v13.i10.724
7. Ma X Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes J. Psychiatr. Res 2020 123 136 144 10.1016/j.jpsychires.2020.02.005 32065949
Ma, X. et al. Alteration of the gut microbiome in first-episode drug-naïve and chronic medicated schizophrenia correlate with regional brain volumes. J. Psychiatr. Res 123, 136–144 (2020).32065949 10.1016/j.jpsychires.2020.02.005
8. Cryan JF The microbiota-gut-brain axis Physiol. Rev. 2019 99 1877 2013 10.1152/physrev.00018.2018 31460832
Cryan, J. F. et al. The microbiota-gut-brain axis. Physiol. Rev. 99, 1877–2013 (2019).31460832 10.1152/physrev.00018.2018
9. Bioque M Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: a narrative review Prog. Neuropsychopharmacol. Biol. Psychiatry 2021 105 110130 10.1016/j.pnpbp.2020.110130 33045322
Bioque, M. et al. Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: a narrative review. Prog. Neuropsychopharmacol. Biol. Psychiatry 105, 110130 (2021).33045322 10.1016/j.pnpbp.2020.110130
10. Lee JJ Gut and oral microbiome modulate molecular and clinical markers of schizophrenia-related symptoms: a transdiagnostic, multilevel pilot study Psychiatry Res. 2023 326 115279 10.1016/j.psychres.2023.115279 37331068
Lee, J. J. et al. Gut and oral microbiome modulate molecular and clinical markers of schizophrenia-related symptoms: a transdiagnostic, multilevel pilot study. Psychiatry Res. 326, 115279 (2023).37331068 10.1016/j.psychres.2023.115279
11. Nguyen TT Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects Schizophr. Res. 2019 204 23 29 10.1016/j.schres.2018.09.014 30268819
Nguyen, T. T. et al. Differences in gut microbiome composition between persons with chronic schizophrenia and healthy comparison subjects. Schizophr. Res. 204, 23–29 (2019).30268819 10.1016/j.schres.2018.09.014
12. Misiak B Gut microbiota alterations in stable outpatients with schizophrenia: findings from a case-control study Acta Neuropsychiatr. 2023 35 147 155 10.1017/neu.2022.38 36503629
Misiak, B. et al. Gut microbiota alterations in stable outpatients with schizophrenia: findings from a case-control study. Acta Neuropsychiatr. 35, 147–155 (2023).36503629 10.1017/neu.2022.38
13. Klee M Education as risk factor of mild cognitive impairment: the link to the gut microbiome J. Prev. Alzheimers Dis. 2024 11 759 768 38706292
Klee, M. et al. Education as risk factor of mild cognitive impairment: the link to the gut microbiome. J. Prev. Alzheimers Dis. 11, 759–768 (2024).38706292
14. Zhao, Q. et al. Gut microbiome and major depressive disorder: Insights from two-sample Mendelian randomization. BMC Psychiatry 24, 493 (2024).
15. Cheng J Gut microbiota-derived short-chain fatty acids and depression: deep insight into biological mechanisms and potential applications Gen. Psychiatr. 2024 37 e101374 10.1136/gpsych-2023-101374 38390241
Cheng, J. et al. Gut microbiota-derived short-chain fatty acids and depression: deep insight into biological mechanisms and potential applications. Gen. Psychiatr. 37, e101374 (2024).38390241 10.1136/gpsych-2023-101374
16. Zhao, Q. et al. Evaluating causal effects of gut microbiome on Alzheimer’s disease. J. Prev. Alzheimers Dis. 11, 1–6 (2024).
17. Liu J Deciphering the ‘gut-brain axis’ through microbiome diversity Gen. Psychiatr. 2023 36 e101090 10.1136/gpsych-2023-101090 37920405
Liu, J. et al. Deciphering the ‘gut-brain axis’ through microbiome diversity. Gen. Psychiatr. 36, e101090 (2023).37920405 10.1136/gpsych-2023-101090
18. Greenland S An introduction to instrumental variables for epidemiologists Int. J. Epidemiol. 2000 29 722 729 10.1093/ije/29.4.722 10922351
Greenland, S. An introduction to instrumental variables for epidemiologists. Int. J. Epidemiol. 29, 722–729 (2000).10922351 10.1093/ije/29.4.722
19. Smith GD Ebrahim S ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 2003 32 1 22 10.1093/ije/dyg070 12689998
Smith, G. D. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 1–22 (2003).12689998 10.1093/ije/dyg070
20. Baranova A Causal associations between major depressive disorder and COVID-19 Gen. Psychiatr. 2023 36 e101006 10.1136/gpsych-2022-101006 37066117
Baranova, A. et al. Causal associations between major depressive disorder and COVID-19. Gen. Psychiatr. 36, e101006 (2023).37066117 10.1136/gpsych-2022-101006
21. Baranova A Causal influences of neuropsychiatric disorders on Alzheimer’s disease Transl. Psychiatry 2024 14 114 10.1038/s41398-024-02822-1 38395927
Baranova, A. et al. Causal influences of neuropsychiatric disorders on Alzheimer’s disease. Transl. Psychiatry 14, 114 (2024).38395927 10.1038/s41398-024-02822-1
22. Baranova A Shared genetics and bidirectional causal relationships between type 2 diabetes and attention-deficit/hyperactivity disorder Gen. Psychiatr. 2023 36 e100996 10.1136/gpsych-2022-100996 36937092
Baranova, A. et al. Shared genetics and bidirectional causal relationships between type 2 diabetes and attention-deficit/hyperactivity disorder. Gen. Psychiatr. 36, e100996 (2023).36937092 10.1136/gpsych-2022-100996
23. Kurilshikov A Large-scale association analyses identify host factors influencing human gut microbiome composition Nat. Genet. 2021 53 156 165 10.1038/s41588-020-00763-1 33462485
Kurilshikov, A. et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat. Genet. 53, 156–165 (2021).33462485 10.1038/s41588-020-00763-1
24. Trubetskoy V Mapping genomic loci implicates genes and synaptic biology in schizophrenia Nature 2022 604 502 508 10.1038/s41586-022-04434-5 35396580
Trubetskoy, V. et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 604, 502–508 (2022).35396580 10.1038/s41586-022-04434-5
25. Sanna S Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases Nat. Genet. 2019 51 600 605 10.1038/s41588-019-0350-x 30778224
Sanna, S. et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat. Genet. 51, 600–605 (2019).30778224 10.1038/s41588-019-0350-x
26. Bowden J Davey Smith G Burgess S Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression Int. J. Epidemiol. 2015 44 512 525 10.1093/ije/dyv080 26050253
Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512–525 (2015).26050253 10.1093/ije/dyv080
27. Verbanck M Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases Nat. Genet. 2018 50 693 698 10.1038/s41588-018-0099-7 29686387
Verbanck, M. et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50, 693–698 (2018).29686387 10.1038/s41588-018-0099-7
28. Staiger D Stock JH Instrumental variables regression with weak instruments Econometrica 1997 65 557 586 10.2307/2171753
Staiger, D. & Stock, J. H. Instrumental variables regression with weak instruments. Econometrica 65, 557–586 (1997).10.2307/2171753
29. Bowden J Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator Genet. Epidemiol. 2016 40 304 314 10.1002/gepi.21965 27061298
Bowden, J. et al. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304–314 (2016).27061298 10.1002/gepi.21965
30. Cheng S Identifying psychiatric disorder-associated gut microbiota using microbiota-related gene set enrichment analysis Brief. Bioinform. 2020 21 1016 1022 10.1093/bib/bbz034 30953055
Cheng, S. et al. Identifying psychiatric disorder-associated gut microbiota using microbiota-related gene set enrichment analysis. Brief. Bioinform. 21, 1016–1022 (2020).30953055 10.1093/bib/bbz034
31. Zheng J Analysis of gut microbiota in patients with exacerbated symptoms of schizophrenia following therapy with amisulpride: a pilot study Behav. Neurol. 2022 2022 4262094 10.1155/2022/4262094 35287288
Zheng, J. et al. Analysis of gut microbiota in patients with exacerbated symptoms of schizophrenia following therapy with amisulpride: a pilot study. Behav. Neurol. 2022, 4262094 (2022).35287288 10.1155/2022/4262094
32. Xu Y Antipsychotic-induced gastrointestinal hypomotility and the alteration in gut microbiota in patients with schizophrenia Brain Behav. Immun. 2022 99 119 129 10.1016/j.bbi.2021.09.014 34563620
Xu, Y. et al. Antipsychotic-induced gastrointestinal hypomotility and the alteration in gut microbiota in patients with schizophrenia. Brain Behav. Immun. 99, 119–129 (2022).34563620 10.1016/j.bbi.2021.09.014
33. Juckel G Impact of Poly I:C induced maternal immune activation on offspring’s gut microbiome diversity—implications for schizophrenia Prog. Neuropsychopharmacol. Biol. Psychiatry 2021 110 110306 10.1016/j.pnpbp.2021.110306 33745977
Juckel, G. et al. Impact of Poly I:C induced maternal immune activation on offspring’s gut microbiome diversity—implications for schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 110, 110306 (2021).33745977 10.1016/j.pnpbp.2021.110306
34. Li S Altered gut microbiota associated with symptom severity in schizophrenia PeerJ 2020 8 e9574 10.7717/peerj.9574 32821537
Li, S. et al. Altered gut microbiota associated with symptom severity in schizophrenia. PeerJ 8, e9574 (2020).32821537 10.7717/peerj.9574
35. Vindegaard N Gut microbial changes of patients with psychotic and affective disorders: a systematic review Schizophr. Res. 2021 234 1 10 10.1016/j.schres.2019.12.014 31952911
Vindegaard, N. et al. Gut microbial changes of patients with psychotic and affective disorders: a systematic review. Schizophr. Res. 234, 1–10 (2021).31952911 10.1016/j.schres.2019.12.014
36. Xiang M Intestinal microbes in patients with schizophrenia undergoing short-term treatment: core species identification based on co-occurrence networks and regression analysis Front. Microbiol. 2022 13 909729 10.3389/fmicb.2022.909729 35783418
Xiang, M. et al. Intestinal microbes in patients with schizophrenia undergoing short-term treatment: core species identification based on co-occurrence networks and regression analysis. Front. Microbiol. 13, 909729 (2022).35783418 10.3389/fmicb.2022.909729
37. Gubert C Microbiome profiling reveals gut dysbiosis in the metabotropic glutamate receptor 5 knockout mouse model of schizophrenia Front. Cell Dev. Biol. 2020 8 582320 10.3389/fcell.2020.582320 33195226
Gubert, C. et al. Microbiome profiling reveals gut dysbiosis in the metabotropic glutamate receptor 5 knockout mouse model of schizophrenia. Front. Cell Dev. Biol. 8, 582320 (2020).33195226 10.3389/fcell.2020.582320
38. Shen Y Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: a cross-sectional study Schizophr. Res. 2018 197 470 477 10.1016/j.schres.2018.01.002 29352709
Shen, Y. et al. Analysis of gut microbiota diversity and auxiliary diagnosis as a biomarker in patients with schizophrenia: a cross-sectional study. Schizophr. Res. 197, 470–477 (2018).29352709 10.1016/j.schres.2018.01.002
39. He Y Gut microbiome and magnetic resonance spectroscopy study of subjects at ultra-high risk for psychosis may support the membrane hypothesis Eur. Psychiatry 2018 53 37 45 10.1016/j.eurpsy.2018.05.011 29870894
He, Y. et al. Gut microbiome and magnetic resonance spectroscopy study of subjects at ultra-high risk for psychosis may support the membrane hypothesis. Eur. Psychiatry 53, 37–45 (2018).29870894 10.1016/j.eurpsy.2018.05.011
40. Li J Clostridiales are predominant microbes that mediate psychiatric disorders J. Psychiatr. Res. 2020 130 48 56 10.1016/j.jpsychires.2020.07.018 32781373
Li, J. et al. Clostridiales are predominant microbes that mediate psychiatric disorders. J. Psychiatr. Res. 130, 48–56 (2020).32781373 10.1016/j.jpsychires.2020.07.018
41. Dunphy-Doherty F Post-weaning social isolation of rats leads to long-term disruption of the gut microbiota-immune-brain axis Brain Behav. Immun. 2018 68 261 273 10.1016/j.bbi.2017.10.024 29104061
Dunphy-Doherty, F. et al. Post-weaning social isolation of rats leads to long-term disruption of the gut microbiota-immune-brain axis. Brain Behav. Immun. 68, 261–273 (2018).29104061 10.1016/j.bbi.2017.10.024
42. Zheng P The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice Sci. Adv. 2019 5 eaau8317 10.1126/sciadv.aau8317 30775438
Zheng, P. et al. The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Sci. Adv. 5, eaau8317 (2019).30775438 10.1126/sciadv.aau8317
43. Chen X Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing Int. J. Leg. Med. 2021 135 131 141 10.1007/s00414-020-02439-1
Chen, X. et al. Profiling the differences of gut microbial structure between schizophrenia patients with and without violent behaviors based on 16S rRNA gene sequencing. Int. J. Leg. Med. 135, 131–141 (2021).10.1007/s00414-020-02439-1
44. Kowalski K Profiling gut microbiota signatures associated with the deficit subtype of schizophrenia: findings from a case-control study Prog. Neuropsychopharmacol. Biol. Psychiatry 2023 127 110834 10.1016/j.pnpbp.2023.110834 37473955
Kowalski, K. et al. Profiling gut microbiota signatures associated with the deficit subtype of schizophrenia: findings from a case-control study. Prog. Neuropsychopharmacol. Biol. Psychiatry 127, 110834 (2023).37473955 10.1016/j.pnpbp.2023.110834
45. Misiak B Associations of gut microbiota alterations with clinical, metabolic, and immune-inflammatory characteristics of chronic schizophrenia J. Psychiatr. Res. 2024 171 152 160 10.1016/j.jpsychires.2024.01.036 38281465
Misiak, B. et al. Associations of gut microbiota alterations with clinical, metabolic, and immune-inflammatory characteristics of chronic schizophrenia. J. Psychiatr. Res. 171, 152–160 (2024).38281465 10.1016/j.jpsychires.2024.01.036
46. Borkent J Role of the gut microbiome in three major psychiatric disorders Psychol. Med. 2022 52 1222 1242 10.1017/S0033291722000897 35506416
Borkent, J. et al. Role of the gut microbiome in three major psychiatric disorders. Psychol. Med. 52, 1222–1242 (2022).35506416 10.1017/S0033291722000897
47. Fond GB Microbiota-orientated treatments for major depression and schizophrenia Nutrients 2020 12 1024 10.3390/nu12041024 32276499
Fond, G. B. et al. Microbiota-orientated treatments for major depression and schizophrenia. Nutrients 12, 1024 (2020).32276499 10.3390/nu12041024
48. Dickerson FB Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial Prim. Care Companion CNS Disord. 2014 16 PCC.13m01579 24940526
Dickerson, F. B. et al. Effect of probiotic supplementation on schizophrenia symptoms and association with gastrointestinal functioning: a randomized, placebo-controlled trial. Prim. Care Companion CNS Disord. 16, PCC.13m01579 (2014).24940526
49. Liu JCW The gut microbiome in schizophrenia and the potential benefits of prebiotic and probiotic treatment Nutrients 2021 13 1152 10.3390/nu13041152 33807241
Liu, J. C. W. et al. The gut microbiome in schizophrenia and the potential benefits of prebiotic and probiotic treatment. Nutrients 13, 1152 (2021).33807241 10.3390/nu13041152
50. Ağagündüz D Probiotics, live biotherapeutic products (LBPs), and gut-brain axis related psychological conditions: implications for research and dietetics Probiotics Antimicrob. Proteins 2023 15 1014 1031 10.1007/s12602-023-10092-4 37222849
Ağagündüz, D. et al. Probiotics, live biotherapeutic products (LBPs), and gut-brain axis related psychological conditions: implications for research and dietetics. Probiotics Antimicrob. Proteins 15, 1014–1031 (2023).37222849 10.1007/s12602-023-10092-4
51. Nita IB Reviewing the potential therapeutic approaches targeting the modulation of gastrointestinal microflora in schizophrenia Int. J. Mol. Sci. 2022 23 16129 10.3390/ijms232416129 36555774
Nita, I. B. et al. Reviewing the potential therapeutic approaches targeting the modulation of gastrointestinal microflora in schizophrenia. Int. J. Mol. Sci. 23, 16129 (2022).36555774 10.3390/ijms232416129
52. Li R Effects of low-frequency rTMS combined with risperidone on the gut microbiome in hospitalized patients with chronic schizophrenia Brain Res. 2023 1819 148539 10.1016/j.brainres.2023.148539 37598899
Li, R. et al. Effects of low-frequency rTMS combined with risperidone on the gut microbiome in hospitalized patients with chronic schizophrenia. Brain Res. 1819, 148539 (2023).37598899 10.1016/j.brainres.2023.148539
